Syphilis Testing Market Size, Share & Trends Analysis Report By Type (Primary Syphilis, Secondary Syphilis), By Test Type (Non-treponemal tests (RPR, VDRL), Treponemal immunoassays (TPPA, TPHA), Enzyme immunoassays (ELISA) & chemiluminescent immunoassays (CLIA), Rapid diagnostic tests (lateral flow immunoassays), Molecular tests (PCR/NAAT), Multiplex STI panels, including syphilis targets), By Technology (Molecular Diagnostics, Immunoassay, Others), By Location of Testing (Laboratory Testing, Point of Care Testing) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Syphilis Testing Market Size & Growth Analysis

The global syphilis testing market size was valued at USD 556.7 million in 2025 and is projected to grow from USD 622.17 million in 2026 to USD 1514.25 million by 2034, registering a CAGR of 11.76% during the forecast period from 2026 to 2034. North America dominated the syphilis testing market with a market share of 42.23% in 2025.

The syphilis testing market comprises diagnostic products and services used to detect Treponema pallidum infection across various stages through laboratory-based evaluations and point-of-care screening methods. The market includes non-treponemal tests such as RPR and VDRL, treponemal immunoassays like TPPA and TPHA, enzyme immunoassays, chemiluminescent assays, rapid lateral flow formats, molecular tools such as PCR, and multiplex STI panels that incorporate syphilis targets. These tests are deployed across commercial laboratories, public health facilities, hospitals, and community-based clinics to support screening, diagnosis, monitoring, and management of syphilis in diverse population groups. Continuous attention toward early detection, rising adoption of structured screening pathways, and expansion of accessible testing sites drive ongoing development of diagnostic offerings within this market.

Type Insights

Secondary syphilis dominated the market as diagnostic centers recorded higher detection rates among individuals presenting with extended symptoms during STI consultations. Clinics observed a steady inflow of patients requiring targeted evaluation for progressing infections, which supported a larger test count in this category. Consistent use of confirmatory examinations across hospitals maintained this segment in a leading position.

Primary syphilis is the fastest-growing segment, with 12.12% as early-stage detection increased across screening drives and routine checkups. Frontline facilities expanded the initial evaluation of high-exposure groups, resulting in more individuals being diagnosed during the first phase of infection. Wider participation in early testing programs supported the rapid advancement of this category.

Request Customizationto receive a tailored report.

Test Type Insights

Treponemal immunoassays dominated the segment with 35.63% due to broad use in confirmatory laboratory workflows where structured evaluation of suspected cases was required. Hospitals and private labs incorporated these assays into routine STI panels, antenatal testing pathways, and follow-up monitoring, ensuring higher volume across the year.

Rapid diagnostic tests is the fastest growing segment with 12.32% as outreach units, community clinics, and mobile programs expanded immediate screening across high traffic areas. Quick availability of test outcomes allowed on-site decision-making during community events and walk-in visits. Rising participation in local screening campaigns strengthened growth in this category.

Technology Insights

Immunoassay dominated the market with 45.64% as laboratories used these systems for large-scale screening and confirmatory evaluation. Diagnostic networks relied on established platforms to process daily sample loads from clinics and public health centers. Strong presence across regional hospitals kept this category ahead of others.

Molecular diagnostics is the fastest-growing segment, with 12.45% driven by increasing use in the detailed evaluation of complex cases and high-risk patients. Facilities conducting expanded STI panels incorporated molecular tools for precise detection of early-stage infections. Greater placement of these systems in select urban labs supported upward growth.

Location of Testing Insights

Laboratory testing dominated the market as hospitals, reference labs, and public facilities conducted structured evaluations for both treponemal and non-treponemal markers. These centers managed steady volumes from outpatient units, maternity clinics, and community referral programs, keeping lab-based testing at the forefront.

Point of care testing is the fastest growing segment, with 12.67% as walk-in clinics, outreach groups, and field units expanded instant screening availability. Broader distribution of rapid kits enabled easier access for individuals seeking immediate testing. Participation in community-level drives pushed this category upward at a strong pace.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America maintained a leading position in the syphilis testing market with a share of 42.23% due to rising screening coverage across hospitals, community health centers, and outreach programs. The region recorded higher test volume as public health agencies expanded community-based screening drives, antenatal syphilis checks, and routine STI assessments. Growth was influenced by the broader deployment of point-of-care tests, the expansion of laboratory automation systems, and improved access to community clinics. Test suppliers continued to introduce assays that support rapid screening, confirmatory lab evaluation, and dual HIV syphilis formats, which encouraged wider adoption across public and private settings.

The U.S. market expanded as states scaled up syphilis testing through public health grants, mobile health units, and federally supported clinics. Demand increased as hospitals incorporated dual testing protocols for patients undergoing routine STI evaluation. Retail clinics and community centers made test access simpler, while electronic reporting systems supported stronger monitoring of regional test uptake. Commercial labs increased their syphilis assay offerings, creating higher throughput in urban and semi-urban regions.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

Asia Pacific recorded the fastest growth of 13.76% driven by rising awareness of congenital syphilis risks, enlargement of maternal care programs, and broader availability of screening tools in urban and semi-urban facilities. Public health authorities strengthened early pregnancy checks, resulting in higher use of both rapid tests and laboratory-based diagnostics. The expansion of online health platforms improved access to test information, encouraging higher participation in community screening efforts.

India’s market advanced as government hospitals added syphilis screening to antenatal visits and private diagnostic chains expanded STI panels. Urban clinics made rapid tests more accessible, while telehealth platforms increased awareness of early detection. Larger cities recorded rising participation in screening campaigns supported by non-profit groups and primary care networks.

Europe Market Insights

Europe moved ahead steadily as countries intensified STI surveillance activities and incorporated syphilis screening into routine diagnostic pathways. Hospitals adopted refined immunoassays for confirmatory evaluation, and primary care facilities increased basic screening checks. Growing interest in digital health reporting and structured public health initiatives contributed to consistent test adoption across multiple care settings.

Germany’s market gained traction as healthcare providers conducted systematic screening among individuals undergoing routine STI checks. Laboratory networks broadened treponemal and non-treponemal test offerings, increasing accessibility. Educational drives run by public health bodies contributed to higher turnout at clinics, driving consistent testing volume.

Middle East and Africa Market Insights

The Middle East and Africa region experienced rising uptake of syphilis testing as urban clinics strengthened STI diagnosis pathways and governments expanded maternal health screening. Imported rapid tests became more widely available through distributors, supporting greater usage in community health facilities. Public health workshops and awareness programs steadily increased recognition of early testing across several countries.

The United Arab Emirates market progressed as private hospitals added syphilis checks to routine sexual health assessments and travelers' screening programs. Diagnostic centers in Dubai and Abu Dhabi increased procurement of rapid tests and immunoassays, widening access. Wellness clinics and expatriate health providers contributed to a steady rise in testing adoption.

Latin America Market Insights

Latin America recorded ongoing progress supported by urban STI clinics, national antenatal care requirements, and government-backed surveillance projects. Community health units expanded access to rapid tests, while partnerships with international agencies improved the supply of diagnostic kits in several countries. Local distributors enhanced the availability of treponemal and non-treponemal assays across retail and clinic channels.

Brazil’s market grew as public hospitals strengthened maternal screening programs and community centers hosted regular walk-in testing days. Diagnostic laboratories adopted improved assay systems to manage rising test volumes. Urban areas recorded higher participation in voluntary testing events, reinforced by municipal outreach programs and medical universities promoting awareness of early detection.

Competitive Landscape

The syphilis testing market is moderately fragmented with a combination of established global diagnostics manufacturers and a rising group of agile innovators specializing in rapid point-of-care screening, multiplex infectious disease testing, and community-level diagnostic access.

BioLytical Laboratories Inc.: An Emerging Market Player

• BioLytical Laboratories Inc. gained recognition as an innovative entrant in the syphilis testing space through its ultra-rapid point-of-care diagnostic technologies. The company is known for developing rapid tests designed to deliver results within minutes, improving the speed and reach of community-based screening programmes. bioLytical focused on expanding its INSTI platform to include syphilis and combined HIV syphilis formats, enabling integrated testing during outreach drives, antenatal care screening and high-volume public health campaigns. Its emphasis on fast turnaround time, ease of use, and deployment in low-resource settings positioned the company as a fast-growing competitor in the global syphilis testing landscape.

List of Key and Emerging Players in Syphilis Testing Market